Infectious Diseases Research

A continuación, se enumeran los ensayos clínicos actuales.

272 estudios en Infectious Diseases Research
(todos los estudios, abiertos o cerrados).

Filtra esta lista de estudios por sede, estatus, etc.

1. A Study to Detect and Candida auris

   Rochester, Minn.

   The purpose of this study is to develop a test that can be used routinely to detect and identify Candida auris from surveillance skin swabs.

    

2. A Study to Evaluate the Cue COVID Rapid Test

   Rochester, Minn.

   The purpose of this study is to to evaluate the analytical performance of the Cue Health rapid (25 minute) molecular test for SARS-CoV-2 RNA using the proprietary nasal sample wand, disposable cartridge, and reader being developed by Cue Health Inc.

3. An Expanded Access Study of Sofosbuvir Combined with Ribavirin and Either with or without Pegylated Interferon for Treating Aggressive Post-Transplant Hepatitis C

   Jacksonville, Fla.

   The purpose of this study, is to open expanded access at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Patients who have an aggressive, recurring hepatitis C infection following liver transplant, will be given sofosbuvir combined with ribavirin, and pegylated interferon may or may not be added at the discretion of the investigator.

4. Registry of Patients Treated With Systemic Mold-Active Triazoles

   Rochester, Minn.

   The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

5. A Study Comparing the Effectiveness and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

   Rochester, Minn.

   The purpose of this study is to assess the effectiveness and safety of giving anti-influenza immune plasma, as an addition to standard of care antivirals, to patients hospitalized with severe influenza A infection.

6. Acupuncture Therapy for COVID-Related Olfactory Loss

   Rochester, Minn.

   The objectives of this study are to describe the incidence of COVID-related olfactory loss, to compare the effectiveness of acupuncture, steroid rinses, and olfactory training versus steroid rinses and olfactory training in the treatment of COVID-related olfactory loss, and to recommend a treatment paradigm for patients with COVID-related olfactory loss.

    

7. A Study of the Use of Quantiferon CMV Blood Test to Find the Length of CMV Prevention in CMV Donor (+) / Recipient (-) Solid Organ Transplant Recipients

   Rochester, Minn.

   The overall aim of this study is to evaluate the clinical utility of the QuantiFERON-CMV test in solid organ transplant recipients on CMV prophylaxis to predict development of CMV disease after completion of prophylaxis. Our hypothesis is that in CMV D+/R- solid organ transplant recipients, the development of immunity as measured by a positive QuantiFERON CMV assay will predict a lower risk of CMV disease after prophylaxis is completed.

8. Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

   Scottsdale/Phoenix, Ariz.

   This study will evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.

9. Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects with Chronic HCV with Advanced Liver Disease or Post-Liver Transplant

   Jacksonville, Fla.

   The purpose of this study is to evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 1 or 4 hepatitis C virus (HCV) infection. Participants will be randomized to receive 12 or 24 weeks of dosing with the LDV/SOF FDC tablet+ribavirin (RBV).

10. Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in Treatment-Naïve HCV Genotype 1-Infected Adults With Chronic Kidney Disease

    Scottsdale/Phoenix, Ariz.

    This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24 week regimen of ombitasvir/ABT-450/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an Estimated Glomerular Filtration Rate (eGFR) <30, including those on hemodialysis.